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INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is a
pandemic disease which affects an estimated 40 million
people world-wide.1 Although the improved strategies of
antiretroviral therapy have reduced morbidity,2 the
SUMMARY
Background: Nutrient malabsorption is a negative prog-
nostic factor in acquired immunodeficiency syndrome
and recent studies have shown that pancreatic insuffi-
ciency is a codetermining factor of malabsorption.
Aims: To evaluate the effectiveness of open-label oral
pancreatic enzyme supplementation therapy in acquired
immunodeficiency syndrome patients with fat malab-
sorption.
Patients and methods: Twenty-four consecutive patients
with human immunodeficiency virus infection and fat
malabsorption were recruited (11 males, 13 females;
median age, 9.1 years). Faecal fat loss was evaluated by
steatocrit assay at entry to the study (T-0), after 2 weeks
(T-1) without pancreatic enzyme treatment and after a
further 2 weeks (T-2) of treatment with pancreatic
extracts (Creon 10 000 at a dose of 1000 units of lipase
per gram of ingested dietary fat). Faecal elastase-1 and
chymotrypsin were assayed at entry.
Results: Six patients (25%) had abnormally low elas-
tase-1 and/or chymotrypsin faecal concentration. In all
patients, steatocrit values were elevated at both T-0 and
T-1. Five patients proved intolerant to pancreatic
enzyme treatment because of the onset of abdominal
pain, and therapy was discontinued. In the 19 patients
who concluded the study, steatocrit values during
pancreatic enzyme treatment (T-2) were significantly
lower than at entry (P < 0.0001). At T-2, in eight of 19
patients, steatocrit values were within the normal limit
and the frequency of cases cured or improved on
pancreatic enzyme therapy (at T-2) was significantly
higher than that observed during the previous study
period without enzyme treatment (T-1) (P < 0.01). A
positive significant correlation was found between
steatocrit values at entry and the Centers for Disease
Control class (P < 0.0005); also, the decrease in
steatocrit values during pancreatic enzyme therapy
(difference between steatocrit value at T-2 and steatocrit
value at T-0) positively correlated with the Centers for
Disease Control class (P < 0.05).
Conclusions: This pilot, open-label study showed that
pancreatic enzyme supplementation therapy is highly
effective in reducing faecal fat loss in human
immunodeficiency virus-infected patients with nutrient
malabsorption. Further double-blind studies must be
undertaken to verify these results and, if they are
confirmed, pancreatic enzymes can be added to our
weapons in the fight against human immunodeficiency
virus-associated nutrient malabsorption.
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prognosis of patients with human immunodeficiency
virus (HIV) infection remains unfavourable. A major
negative prognostic factor in AIDS is the onset of
nutrient malabsorption which contributes to malnutri-
tion. Several studies have underlined the important role
of intestinal damage in determining protein loss and
increased intestinal permeability.3–6 However, our
recent studies have demonstrated that pancreatic
insufficiency is quite frequent in both children7 and
adults8 with AIDS, and a significant negative correla-
tion was found between the degree of steatorrhoea and
the faecal concentration of the pancreatic enzymes.7
Consequently, pancreatic insufficiency plays a role in
determining nutrient malabsorption in AIDS. Therefore,
it could be hypothesized that treatment with pancreatic
extracts should improve nutrient absorption in AIDS
patients with malabsorption syndrome. However, to
date, no studies have been performed to consider this
possibility.
As the first phase of testing this hypothesis, we have
evaluated the effect of 2 weeks of open-label oral
pancreatic enzyme supplementation therapy on faecal
fat excretion in HIV-infected patients with fat malab-
sorption.
PATIENTS
From a total of 85 patients examined at the out-patients
clinics of two tertiary care centres for paediatric HIV
infection, between October 1997 and March 1998, we
recruited all consecutive subjects with steatorrhoea. In
this way, 24 children (11 males, 13 females; median
age, 9.1 years; range, 1–14 years) were enrolled. At the
time of the study, none of the patients were receiving
the highly active antiretroviral combination therapy,2
as the protocol was begun before the routine introduc-
tion of this treatment. The following information was
obtained for each child: (a) HIV class according to the
Center for Disease Control (CDC) criteria;9 (b) CD4
lymphocyte count; (c) patient’s weight expressed as
weight Z-score; (d) presence of opportunistic infections;
(e) drug treatment, including zidovudine, dideoxydano-
sine, cotrimoxazole and pentamidine; (f) presence of
diarrhoea (defined as three or more unformed or liquid
stools per day). The weight Z-score was calculated as
follows: Z-score  (observed weight – mean weight for
sex and age)/standard deviation for sex and age; as in
our previous study,10 Italian regional standards were
used as reference values.
Out-patient subjects without steatorrhoea at the time
of the first evaluation were not included in the study or
investigated further.
Informed consent was obtained from the parents or the
legal guardians of the children.
The study protocol was approved by the Ethics
Committee of the University Hospital.
STUDY DESIGN
All the consecutive patients with steatorrhoea under-
went a pre-study assessment within 1 week before the
study started; they were put on a standard diet and,
after 1 week, steatorrhoea determination and faecal
pancreatic function tests were performed (time T-0). All
the patients with confirmed steatorrhoea at this time
continued to be studied, regardless of the pancreatic
function test results. Steatorrhoea was then re-evaluated
after 2 weeks without pancreatic enzyme therapy (time
T-1). Finally, pancreatic supplementation treatment
was started and, 4 weeks after the beginning of the
study (2 weeks after the beginning of treatment),
steatorrhoea was again evaluated (time T-2).
The pancreatic supplementation therapy adminis-
tered was Creon 10 000 at a dose of 1000 units of
lipase per gram of ingested dietary fat. The declared
enzyme activity units (unit of the Fe´de´ration Interna-
tionale Pharmaceutique) per capsule of Creon were as
follows: lipase, 10 000 U; amylase, 8000 U; protease,
600 U. Between four and nine pancreatic enzyme
capsules were consumed daily, according to the
different dietary fat intakes of each patient. Pill counts
were performed halfway through the study and at the
end.
During the various study periods, the patients main-
tained a standard diet containing approximately 2 g of
fat/kg body weight. A dietary chart containing a list of
different foods with the relative fat contents was given
to patients’ parents and they were instructed to fill in
the dietary chart every day with the aid of dieticians.
Furthermore, the parents were able to contact the
reference centres whenever necessary, and frequent
telephone contacts helped to ensure adherence to the
therapy and diet.
Definition of response
During pancreatic enzyme therapy, a full response to
treatment was defined as normalization of steatocrit in a
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subject with baseline elevated values; a partial response
was defined as a reduction in steatocrit values below
baseline, but without achieving normalization; a lack of
response was defined as evidence of steatocrit values
equal to or higher than at baseline.
Evaluation of side-effects
During the 4-week study period, the parents recorded
any clinical symptoms and the patients were
re-examined in hospital for any adverse reactions at
the end of the study. Drug administration was stopped
when a clinical reaction occurred. Complete blood
count and serum chemistry panel were assayed both
at baseline and at the end of the study, following
pancreatic enzyme supplementation therapy.
METHODS
Stools were collected over 24 h from children receiving
a standard diet (carbohydrates 50–60% of total calories,
proteins 12–15% and fats approximately 30%); they
were subsequently homogenized, weighed and stored at
)20 °C. An aliquot was used to determine faecal
enzymes in the Division of Internal Medicine laboratory
of the University of Palermo. Another aliquot was
used to determine lipid faecal concentration in the
Department of Paediatrics laboratory of the University
of Naples.
Steatorrhoea determination
Faecal fat excretion was quantitatively estimated by the
steatocrit method, as previously reported.11 In brief,
0.5 g stools were further homogenized with 0.06 g sand
and 2 volumes water, and 70 lL was introduced into a
microhaematocrit tube, which was sealed with wax and
centrifuged for 15 min at 12 000 rev/min. After cen-
trifugation, a lower layer composed of non-fatty faecal
solids (S) and a liquid intermediate layer were invariably
present. In patients with steatorrhoea, the tubes showed
three different layers, as a third upper fatty layer (F) was
evident. Steatocrit was expressed as a percentage using
the following formula: Steatocrit  F/(S + F) · 100.
The upper limit for normal steatocrit values was selected
as 2%, as this is the highest value observed in our
laboratory for healthy subjects in the age range
considered.11 It has been previously shown that the
mean interday coefficient of variation can be as low as
2% and does not exceed 20%;12 therefore, the 24-h
steatocrit can be regarded as having a narrow variab-
ility range.
Pancreatic function tests
Pancreatic function was investigated by two distinct
non-invasive tests: the quantitative determinations of
elastase-1 concentration and chymotrypsin activity in
faecal specimens. Elastase-1 concentration was deter-
mined by a commercially available enzyme-linked
immunoabsorbent assay test, which uses two mono-
clonal antibodies against two distinct specific epitopes
of human pancreatic elastase (Schebo-tech, Wetten-
berg, Germany). Results were expressed as lg/g of
stools or as lg/24 h. The lower normal limit of
elastase-1 was 200 lg/g of stools or 10 000 lg/
24 h.7, 8, 13 Chymotrypsin activity was determined at
37 °C by a photometric assay (Monotest Chymotrypsin,
Boehringer, Mannheim, Germany). Results were
expressed as U/g of stools or as U/24 h. The lower
normal limit was 7.5 U/g or 375 U/24 h. The cut-off
limits were derived from data obtained in the same
laboratory in 300 age-matched healthy controls.14
Both elastase-1 and chymotrypsin activities were
determined on specimens kept frozen for up to 30 days.
Previous data showed that cold storage did not modify
the results, the interassay coefficient of variation being
9.8% for chymotrypsin and 8.3% for elastase-1.
STATISTICAL ANALYSIS
Student’s t-test for paired data was used to compare the
steatocrit values recorded at the pre-study assessment
(T-0), during the wash-out period (T-1) and during
pancreatic enzyme treatment (T-2). Fisher’s exact test
was used to compare the frequency of cases showing
normal steatocrit values with and without pancreatic
supplementation therapy. The chi-squared test for trend
was used to compare the frequency of cases showing
cured, improved or unchanged fat malabsorption with
and without pancreatic enzyme supplementation ther-
apy. The response rate to treatment was calculated
based on an intention-to-treat 24 patients.
Spearman’s correlation coefficient r was applied to
determine the significance of the correlation between
baseline steatocrit values (steatocrit at T-0) and the
modifications in steatocrit values during the different
phases of the study (steatocrit values at T-2 – steatocrit
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values at T-0) vs. CDC class, weight Z-score and CD4
count.
RESULTS
The 24 children enrolled were classified according to
their HIV infection state as follows: 9 C3, 1 C2, 1 C1, 6
B3, 3 B2, 2 A3, 2 A2.
All the recruited patients had confirmed elevated
steatocrit values at the pre-study assessment (T-0).
Furthermore, with regard to the pancreatic function
tests, six patients (25%) had abnormally low elastase-1
and/or chymotrypsin faecal concentration. Of these six
children, three had isolated elastase-1 deficiency, one
isolated chymotrypsin deficiency and two deficiency in
both pancreatic enzymes. Diarrhoea was observed in 14
children.
After the first 2 weeks of the study period (T-1),
without any pancreatic supplementation therapy, the
patients underwent another 24-h stool collection to
determine steatocrit values: all were confirmed as
having steatorrhoea as none had a normal steatocrit
and values were not different from the baseline
assessment (T-0) (Table 1).
Thus, they were started on pancreatic enzyme
therapy. However, in five of the 24 patients, treat-
ment was withdrawn due to the onset of abdominal
pain. This appeared within the first 2–5 days of
treatment and disappeared within 24 h after drug
withdrawal, indicating a close relationship with
pancreatic enzyme therapy. Nineteen patients comple-
ted the study and underwent a third steatocrit
determination, after 2 weeks of pancreatic enzyme
therapy. At this time (T-2), steatocrit was normal in
eight of 19 patients and, in the whole study group,
the mean steatocrit value was significantly lower than
at the two previous determinations (P < 0.0001)
(Table 1). In each patient who completed the study,
steatocrit values were lower during pancreatic enzyme
treatment than at the two previous determinations
(Figure 1).
Table 2 shows the response rate of pancreatic enzyme
therapy in comparison with the time of entry to the
study, considering all the 24 patients initially included
in the study. On pancreatic extracts, steatorrhoea
decreased in 11 of 24 subjects and disappeared in eight
of 24 subjects. In contrast, the comparison between
baseline data and those obtained after the first 2 weeks
of the study (during which no enzymatic treatment was
given) showed that steatorrhoea did not completely
regress in any of the patients at this stage. Statistical
analysis showed that the frequency of cases cured or
improved on pancreatic enzyme therapy (at T-2) was
significantly higher than that observed during the
previous study period without enzyme treatment (T-1)
(P < 0.01; chi-squared test for trend  6.63). The
frequency of normal steatocrit results was significantly
higher during pancreatic enzyme treatment than in the
previous period (8/24 cases vs. 0/24; P < 0.005;
Fisher’s test).
A positive significant correlation was detected between
steatocrit values at entry and the CDC class (Spearman’s
coefficient r: r  0.60; P < 0.0005) (Figure 2). Also,
the decrease in steatocrit values during pancreatic
enzyme therapy (difference between steatocrit value at
T-2 and steatocrit value at T-0) positively correlated
with the CDC class (Spearman’s coefficient r: r  0.38;
P  0.05). No significant correlation was found
between steatocrit values at baseline and steatocrit
decrease during pancreatic enzyme therapy and CD4+
count or weight Z-score.
All of the six patients who had low elastase-1 and/or
chymotrypsin values at entry to the study completed the
protocol: on pancreatic enzyme treatment, three
patients normalized and the other three had lower
steatocrit values than during the previous study phases.
Twelve of the 14 patients with diarrhoea at entry to
the study completed the protocol: diarrhoea disappeared
in only three during pancreatic enzyme treatment,
whereas in the other nine it persisted.
During the whole study period, patients were in a
stable clinical condition and there was no modification
Table 1. Mean steatocrit values  s.d. (%) and number of cases
with normal steatocrit in the 19 HIV-infected patients who
completed the study, at entry to the study (T-0), after 2 weeks
without pancreatic enzyme therapy (T-1) and after 2 weeks of
treatment with pancreatic extracts (T-2)
T-0 T-1 T-2
Steatocrit value 7.4  2.6* 7.3  3.7* 3.9  2.1*
Number of cases with
normal steatocrit values
0/19 0/19 8/19
Five of the 24 patients originally included did not complete the study
due to intolerance to pancreatic enzyme treatment (see Results
section).
* T-0 vs. T-1, not significant; T-0 vs. T-2, P < 0.0001 (t = 7.406;
Student’s t-test for paired data); T-1 vs. T-2, P < 0.0001 (t = 7.158;
Student’s t-test for paired data).
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in the long-term therapy (antiretroviral therapy, anti-
biotics, etc.). There was no difference in the incidence of
opportunistic infections.
Daily dietary fat intake per kilogram of body weight
was substantially identical during the two study periods
(mean  s.d. values: 2.2  0.3 g/kg body weight at
T-1; 2.3  0.2 g/kg body weight at T-2).
No variations were observed in blood count and serum
chemistry panel before and after pancreatic enzyme
supplementation.
DISCUSSION
Two-thirds of patients with AIDS will have diarrhoea at
some time during the course of their illness15 and a
large number will suffer from chronic diarrhoea and
malabsorption syndrome.3, 4 Nutrient malabsorption is
certainly a major clinical problem as it contributes to
malnutrition, thereby increasing the progression of HIV
disease.16 As a consequence, in HIV patients with
nutrient malabsorption, any treatment which could
reduce its severity is highly relevant. Although most of
the studies on malabsorption syndrome in AIDS have
underlined the role of intestinal mucosa damage,3–6
more recently greater attention has been dedicated to
the role of pancreatic impairment. Autopsy studies have
shown severe pancreatic lesions in up to 90% of HIV-
infected patients.17, 18 Functional studies have demon-
strated a high incidence of abnormalities in HIV-infected
patients.7, 8, 19 Overall, we have found steatorrhoea in
26% of consecutive HIV-infected children7 and in 71%
of adults.8 Furthermore, abnormal pancreatic function
tests were significantly associated with steatorrhoea.7 It
has been estimated that not less than 30% of patients
have steatorrhoea because of pancreatic dysfunction.
These data suggested the opportunity of a trial with
pancreatic enzyme therapy in AIDS. However, because
oral pancreatic enzyme therapy represented a novel
approach to treating nutrient malabsorption in HIV-
infected patients and therefore implied a risk of poor
tolerance, it was decided to undertake an unblind, open-
label study to establish the safety of treatment and its
Figure 1. Individual steatocrit values
recorded at each of the three study times: 1,
baseline evaluation at entry to the study; 2,
second evaluation, without pancreatic
enzyme treatment; 3, third evaluation on
oral pancreatic enzyme treatment. Dotted
line, high normal limit. Five of the 24
patients originally included did not
complete the study due to intolerance to
pancreatic enzyme treatment (see Results
section).
Table 2. Response rate (number of cases
and percentage) of pancreatic enzyme
therapy in comparison with the previous
period during which no enzymatic
treatment was given. All 24 patients
initially included in the study were
considered
Lack of
response
Partial
response*
Complete
response*
On pancreatic enzyme therapy 5/24  (19%) 11/24 (48%) 8/24 (33%)
Without pancreatic enzyme therapy 9/24 (39%) 15/24 (61%) 0/24 (0%)
Chi-squared test for trend = 6.63, P < 0.01.
* Complete response was defined as full normalization of steatocrit values; partial response was
defined as a reduction in steatocrit values below baseline steatocrit values but still exceeding
the normal limit (i.e. for ‘pancreatic enzyme therapy period’ T-2 vs. T-0; for ‘pancreatic
enzyme wash-out period’ T-1 vs. T-0).
  The five patients with lack of response on pancreatic enzyme therapy were those who did not
complete the study due to intolerance to pancreatic enzyme treatment (see Results section).
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efficacy as judged by fat absorption. The results indicate
that supplementation therapy with pancreatic enzymes is
able to reduce, or even completely abolish, fat malab-
sorption in HIV-infected patients. In fact, while on
pancreatic enzyme treatment, steatorrhoea disappeared
in one-third of patients originally included (8/24 cases)
and steatocrit values fell in every subject who completed
the study. Statistical analysis demonstrated that, during
pancreatic supplementation therapy, steatocrit values
were significantly lower than at entry. Obviously, this
result could be extremely relevant if it is confirmed by
further double-blind, placebo-controlled studies.
In this study, it was first shown that the severity of
steatorrhoea and the subsequent improvement in fat
absorption on enzyme treatment were related to more
advanced HIV disease. In fact, both steatocrit values at
entry and the decrease in steatocrit values on enzyme
therapy significantly correlated with the CDC class
(Figure 2), an index which evaluates the general
condition of AIDS patients, taking into account clinical,
immunological and nutritional status. Thus, the more
severe the clinical condition, the more severe the
steatorrhoea and the greater the improvement in fat
absorption on pancreatic enzyme therapy.
However, some points deserve additional comments.
First, this study fully confirms the lack of correspon-
dence between the presence of steatorrhoea and diar-
rhoea in HIV-infected patients;2, 4, 7 in fact, at entry,
only 14 of the 24 patients showed diarrhoea. Further-
more, at the end of the study, although all patients
benefitted from pancreatic treatment in terms of reduc-
tion in fat malabsorption, only in one-quarter of those
with diarrhoea was this symptom cured. Thus, pancre-
atic supplementation therapy could be useful in reduced
stool fat loss, but only in a minority of the patients was
it able to cure the diarrhoea, which evidently has a
multiple pathogenesis and is probably mainly dependent
on intestinal mucosa damage.4–6 Second, oral pancre-
atic enzymes can produce abdominal pain and 20% of
the patients included in this study had to suspend the
treatment. Although this side-effect was foreseeable, we
had never observed it in previous trials in patients with
coeliac disease10 or cystic fibrosis.20 Third, it is some-
how surprising that the efficacy of supplementation
therapy on steatorrhoea was not limited to patients with
abnormal pancreatic function. It is possible that faecal
elastase-1 and chymotrypsin determinations were not
sensitive enough to reveal a mild degree of pancreatic
dysfunction in AIDS patients, although it is an accepted
concept that steatorrhoea due to pancreatic insuffi-
ciency is always associated with severe pancreatic
insufficiency. It is conceivable that oral pancreatic
enzymes modify the intestinal environment producing
a direct effect against the overgrowth of bacteria in the
duodenum and jejunum, with a consequent positive
effect on intestinal absorptive capacity.
However, the beneficial effects of oral pancreatic
enzyme therapy on fat absorption may be due to the
natural course of the disease or be caused by a placebo
effect of the treatment; in fact, it cannot be excluded
that, during the course of the disease, there may have
been a spontaneous remission of the fat malabsorption.
Finally, it must be remembered that this study was
carried out before the routine introduction of highly
active antiretroviral therapy2 which has been shown to
significantly improve intestinal function in HIV-infected
patients.21 Thus, the effectiveness of pancreatic enzyme
treatment must be re-evaluated, taking the new thera-
peutic strategies into account. However, in the ‘new
antiretroviral era’, pancreatic enzyme treatment could
be considered for the millions of people in the ‘Third
World’ who do not have access to the new anti-HIV
drugs.
In summary, this pilot, open-label study showed that:
(a) pancreatic enzyme supplementation therapy is
highly effective in reducing faecal fat loss in HIV-
infected patients with nutrient malabsorption; (b) there
Figure 2. Relation between the steatocrit values at entry to the
study and HIV clinical category (Center for Disease Control, CDC,
classes). CDC class A, mild or no signs/symptoms; CDC class B,
moderate signs/symptoms; CDC class C, severe signs/symptoms.
Five of the 24 patients originally included did not complete the
study due to intolerance to pancreatic enzyme treatment (see
Results section).
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is a direct correlation between the clinical condition of
the patients and the severity of steatorrhoea. Further
double-blind studies must verify these results and, if
they are confirmed, pancreatic enzymes can be added to
our weapons in the fight against nutrient malabsorption
in AIDS.
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